Thermo Fisher Scientific Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 4/6
Thermo Fisher Scientific yıllık ortalama 5.9% oranında kazançlarını artırırken, Life Sciences sektöründe kazançlar growing at 12.7% annual. Gelirler growing yılda ortalama 10.9% oranında artmaktadır. Thermo Fisher Scientific'in özkaynak karlılığı 12.5% ve net marjı 14.5%'dir.
Anahtar bilgiler
5.9%
Kazanç büyüme oranı
6.7%
EPS büyüme oranı
Life Sciences Sektör Büyümesi | 21.5% |
Gelir büyüme oranı | 10.9% |
Özkaynak getirisi | 12.5% |
Net Marj | 14.5% |
Son Kazanç Güncellemesi | 28 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Thermo Fisher Scientific Q3: Expecting Market Recovery In FY25; Upgrade To 'Buy'
Oct 23Thermo Fisher Scientific: Fantastic Company, Rich Valuation
Oct 04These 4 Measures Indicate That Thermo Fisher Scientific (NYSE:TMO) Is Using Debt Reasonably Well
Sep 21Thermo Fisher Scientific Inc.'s (NYSE:TMO) Price Is Out Of Tune With Earnings
Aug 16Thermo Fisher Scientific: Microscopic Signs Of Growth Emerging
Jul 25A Look At The Fair Value Of Thermo Fisher Scientific Inc. (NYSE:TMO)
Jul 11Is Thermo Fisher Scientific (NYSE:TMO) A Risky Investment?
Jun 18Low Yield, High Growth: Unveiling The Power Of Thermo Fisher's Dividends
Jun 07Thermo Fisher: Renewed Growth Yet To Materialize, But Already Priced In (Rating Downgrade)
Apr 30Thermo Fisher Scientific Inc. (NYSE:TMO) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Apr 27Why Thermo Fisher Scientific Inc. (NYSE:TMO) Could Be Worth Watching
Apr 24Thermo Fisher Scientific: Too Hot To Handle
Apr 15Investors Still Waiting For A Pull Back In Thermo Fisher Scientific Inc. (NYSE:TMO)
Apr 02We Think Thermo Fisher Scientific (NYSE:TMO) Can Stay On Top Of Its Debt
Mar 12Thermo Fisher's Bright Future Makes It A Great Buy On Weakness
Feb 06Here's What Analysts Are Forecasting For Thermo Fisher Scientific Inc. (NYSE:TMO) After Its Yearly Results
Feb 02Thermo Fisher: Blue Chip Stock Melded With Growth Characteristics
Jan 16Thermo Fisher: Downturn In Pharma And Biotech And Weak China Growth; Initiate With 'Hold'
Jan 06Is Now An Opportune Moment To Examine Thermo Fisher Scientific Inc. (NYSE:TMO)?
Dec 29Does Thermo Fisher Scientific (NYSE:TMO) Have A Healthy Balance Sheet?
Dec 11Thermo Fisher Scientific: I Am Still Waiting For An Attractive Buying Opportunity.
Dec 02Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Could Be 25% Below Their Intrinsic Value Estimate
Nov 07Gelir ve Gider Dağılımı
Thermo Fisher Scientific nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
28 Sep 24 | 42,370 | 6,135 | 8,512 | 1,343 |
29 Jun 24 | 42,346 | 6,220 | 8,469 | 1,316 |
30 Mar 24 | 42,492 | 6,034 | 8,434 | 1,322 |
31 Dec 23 | 42,857 | 5,995 | 8,381 | 1,337 |
30 Sep 23 | 43,421 | 5,941 | 8,464 | 1,401 |
01 Jul 23 | 43,524 | 5,721 | 8,653 | 1,433 |
01 Apr 23 | 43,807 | 6,024 | 8,781 | 1,453 |
31 Dec 22 | 44,915 | 6,950 | 8,940 | 1,471 |
01 Oct 22 | 44,167 | 7,032 | 8,854 | 1,472 |
02 Jul 22 | 42,820 | 7,439 | 8,611 | 1,472 |
02 Apr 22 | 41,123 | 7,603 | 8,317 | 1,450 |
31 Dec 21 | 39,211 | 7,725 | 7,857 | 1,406 |
02 Oct 21 | 39,059 | 8,565 | 7,843 | 1,390 |
03 Jul 21 | 38,250 | 8,596 | 7,462 | 1,335 |
03 Apr 21 | 35,894 | 7,924 | 7,199 | 1,256 |
31 Dec 20 | 32,218 | 6,375 | 6,940 | 1,181 |
26 Sep 20 | 28,497 | 4,879 | 6,360 | 1,067 |
27 Jun 20 | 26,248 | 3,706 | 6,292 | 1,018 |
28 Mar 20 | 25,647 | 3,669 | 6,114 | 1,000 |
31 Dec 19 | 25,542 | 3,696 | 6,139 | 1,003 |
28 Sep 19 | 25,220 | 3,592 | 6,060 | 992 |
29 Jun 19 | 24,868 | 3,541 | 6,025 | 985 |
30 Mar 19 | 24,630 | 3,174 | 6,033 | 981 |
31 Dec 18 | 24,358 | 2,938 | 6,022 | 967 |
29 Sep 18 | 23,898 | 2,570 | 6,022 | 949 |
30 Jun 18 | 23,094 | 2,395 | 5,888 | 926 |
31 Mar 18 | 22,006 | 2,256 | 5,632 | 906 |
31 Dec 17 | 20,918 | 2,228 | 5,428 | 887 |
30 Sep 17 | 19,824 | 2,330 | 5,214 | 867 |
01 Jul 17 | 19,199 | 2,270 | 5,064 | 833 |
01 Apr 17 | 18,744 | 2,174 | 4,999 | 794 |
31 Dec 16 | 18,274 | 2,025 | 4,883 | 754 |
01 Oct 16 | 17,973 | 1,999 | 4,814 | 723 |
02 Jul 16 | 17,606 | 2,003 | 4,711 | 711 |
02 Apr 16 | 17,341 | 1,998 | 4,639 | 703 |
31 Dec 15 | 16,965 | 1,980 | 4,566 | 692 |
26 Sep 15 | 16,806 | 1,978 | 4,633 | 695 |
27 Jun 15 | 16,854 | 1,971 | 4,732 | 698 |
28 Mar 15 | 16,905 | 1,738 | 4,823 | 707 |
31 Dec 14 | 16,890 | 1,896 | 4,788 | 691 |
27 Sep 14 | 15,864 | 1,635 | 4,415 | 613 |
28 Jun 14 | 14,884 | 1,482 | 4,031 | 534 |
29 Mar 14 | 13,802 | 1,481 | 3,638 | 447 |
31 Dec 13 | 13,090 | 1,279 | 3,373 | 396 |
Kaliteli Kazançlar: TMO yüksek kaliteli kazançlar sağlıyor.
Büyüyen Kar Marjı: TMO 'nin mevcut net kar marjları (14.5%) geçen yılın (13.7%) sinden daha yüksektir.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: TMO şirketinin kazancı son 5 yılda yılda 5.9% oranında arttı.
Büyüme Hızlandırma: TMO 'un son bir yıldaki kazanç büyümesi ( 3.3% ) 5 yıllık ortalamasının ( 5.9% /yıl) altındadır.
Kazançlar vs. Sektör: TMO geçen yılki kazanç büyümesi ( 3.3% ) Life Sciences sektörünün -4.7% değerini aştı.
Özkaynak Getirisi
Yüksek ROE: TMO 'nin Özsermaye Getirisi ( 12.5% ) düşük olarak değerlendiriliyor.